EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Treatment Monitoring and Outcome Prediction in Invasive Aspergillosis Using Immunologic Markers

Ana Pereira, Jennifer Scott, Andrei Sarlea, Rosanne Sprute, Robina Aerts iD, Cornelia Lass-Flörl iD, Malgorzata Mikulska iD, Sarah Sedik iD, Carolina Garcia-Vidal, Jean-Pierre Gangneux iD, Daniele R Giacobbe iD, Juergen Prattes iD und 11 weitere

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag140 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Ana Pereira und 22 weiteren Autor:innen. Beteiligte Einrichtung: Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal. Hauptthemen laut MEDLINE: Biomarkers, Antifungal Agents, Aspergillosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Investigator Initiated Research, Gilead Sciences, Treatment Monitoring and Diagnosis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Invasive aspergillosis (IA) is a leading cause of mortality despite antifungal therapy. Current biomarkers for treatment monitoring and outcome prediction are limited, with host biomarkers showing potential in other fungal diseases but not in IA yet.

Methods

In this ECMM multicenter study, we prospectively evaluated a cohort of 51 patients with probable or proven IA with underlying hematological malignancies. Serial serum samples, collected over a 3-week period, were analyzed using the Olink Target 96 Inflammation panel. Differential expression analyses and survival analysis for outcome prediction were performed.

Results

Early after treatment, all differentially expressed proteins were upregulated in patients showing clinical improvement compared with those with worsening disease, with the exception of CCL23. Multiple proteins significantly correlated with the need to switch from primary to salvage antifungal therapy. For late treatment response, matrix metalloproteinase-10 (MMP-10) emerged as predictor, with consistently lower expression during clinical improvement during Weeks 2 and 3. Moreover, low-serum concentrations of CXCL6 at Week 2 and MMP-10 at Week 3 were associated with higher survival probability.

Conclusions

The dynamics of immune markers across disease states may help predicting responses to antifungal treatment. Future studies should establish their usefulness in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersAntifungal AgentsAspergillosisHumansFemaleProspective StudiesMaleTreatment OutcomeMiddle AgedAdultHematologic Neoplasms

Stichwörter der Autor:innen

aspergillosisbiomarkersinvasive fungal infectionsproteomicstreatment monitoring

Substanzen

BiomarkersAntifungal Agents

Autor:innen und Institutionen

  • Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.
  • ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
  • Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Faculty of Medicine and University Hospital Cologne, University of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Ger…
  • Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Division of Infectious Diseases, Excellence Center for Medical Mycology (ECMM), and Center for Integrated Oncology Aachen Bonn Colo…
  • German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne Department, Cologne, Germany.

ORCID-Profile: Robina Aerts, Cornelia Lass-Flörl, Malgorzata Mikulska, Sarah Sedik, Jean-Pierre Gangneux, Daniele R Giacobbe, Juergen Prattes, Jan Grothe, Vinod Kumar, Agostinho Carvalho, Martin Hoenigl

Förderung

  • Investigator Initiated Research
  • Gilead Sciences
  • Treatment Monitoring and Diagnosis
  • Fundação para a Ciência e a Tecnologia
  • EU Horizon

Zitieren

APA

Pereira, A., Scott, J., Sarlea, A., Sprute, R., Aerts, R., Lass-Flörl, C., Mikulska, M., Sedik, S., Garcia-Vidal, C., Gangneux, J. P., Giacobbe, D. R., Prattes, J., Grothe, J., Biswas, S., Monzo-Gallo, P., Bassetti, M., Maertens, J., Kumar, V., Koehler, P., …, & Hoenigl, M. (2026). Treatment Monitoring and Outcome Prediction in Invasive Aspergillosis Using Immunologic Markers. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag140

Vancouver

Pereira A, Scott J, Sarlea A, Sprute R, Aerts R, Lass-Flörl C, et al. Treatment Monitoring and Outcome Prediction in Invasive Aspergillosis Using Immunologic Markers. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag140

BibTeX
@article{Pereira2026,
  author = {Pereira, Ana and Scott, Jennifer and Sarlea, Andrei and Sprute, Rosanne and Aerts, Robina and Lass-Flörl, Cornelia and Mikulska, Malgorzata and Sedik, Sarah and Garcia-Vidal, Carolina and Gangneux, Jean-Pierre and Giacobbe, Daniele R and Prattes, Juergen and Grothe, Jan and Biswas, Subhra and Monzo-Gallo, Patricia and Bassetti, Matteo and Maertens, Johan and Kumar, Vinod and Koehler, Philipp and Cunha, Cristina and Netea, Mihai G and Carvalho, Agostinho and Hoenigl, Martin},
  title = {Treatment Monitoring and Outcome Prediction in Invasive Aspergillosis Using Immunologic Markers},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag140}
}
Kostenlos starten →